Head & Neck/Thyroid Cancers
From the Journals
Most Targeted Cancer Drugs Lack Substantial Clinical Benefit
Researchers assess validity of the molecular targets and clinical benefits of genome-targeted cancer drugs approved in the United States from 2015...
Conference Coverage
No Routine Cancer Screening Option? New MCED Tests May Help
CanScan, MERCURY, and OncoSeek can detect a range of cancers and recognize the tissue of origin with high accuracy.
From the Journals
Oncologists Voice Ethical Concerns Over AI in Cancer Care
Researchers ask 204 oncologists from 37 states for their views on the ethical implications of using AI for cancer care.
From the Journals
GLP-1 Receptor Agonists Don’t Raise Thyroid Cancer Risk
Researchers compared data from 145,410 patients who initiated GLP-1 RAs and 291,667 patients initiating dipeptidyl peptidase 4 (DPP4) inhibitors...
Conference Coverage
Circulating Tumor DNA Predicts Early Treatment Response in Patients With HER2-Positive Cancers
New study results suggest ctDNA dynamics provide an early window into predicting response to targeted therapies in patients with HER2-altered...
Conference Coverage
Repeat MCED Testing May ID Early-Stage and Unscreened Cancers
Eight of 26 patients with cancer signals detected through MCED had cancer.
From the Journals
Less Than 50% of Accelerated Approvals Show Clinical Benefit
Researchers review 46 cancer drugs granted accelerated approvals between 2013 and 2017.
From the Journals
Virtual Reality Brings Relief to Hospitalized Patients With Cancer
Patients were randomized to receive either 10 minutes of immersive VR distraction therapy or 10 minutes of two-dimensional guided imagery...
Feature
Should Opioids Be Used for Chronic Cancer Pain?
Prescribing strategies are partly driven by peer pressure, new research suggests.
Commentary
A Banned Chemical That Is Still Causing Cancer
This carcinogen ‘is still around: in our soil, in our food, and in our blood.’
From the Journals
Active Surveillance for Cancer Doesn’t Increase Malpractice Risk
Researchers identify malpractice trends involving active surveillance related to thyroid, prostate, kidney, and...